Reported efficacy outcomes (HRs [95% CI] vs warfarin) of the respective NOACs in the phase 3 trials [1]–[5] in the intent-to-treat analysis.
收藏数据链接：
官方服务：
资源简介：
AP, apixaban; CI, confidence interval; DE, dabigatran etexilate; EDOX, edoxaban; HR, hazard ratio; RIVA, rivaroxaban. Note. Bold font marks results where the 95% CIs do not cross or touch 1.00.*Dose with most pronounced efficacy result. †Includes ischemic strokes only.
创建时间：
2015-12-02
